Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

Journal Articles

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nicholas Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1952.

https://doi.org/10.1182/blood.V110.11.1952.1952

Published: 2007

Journal Articles

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Deborah Thomas, M.D., Charles Koller, M.D., Jenny Shan, Jorge Cortes, M.D.

Blood (2007) 110 (11): 1955.

https://doi.org/10.1182/blood.V110.11.1955.1955

Published: 2007

Journal Articles

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Jorge Cortes, M.D., Nicholas Donato, Ph.D.

Blood (2007) 110 (11): 1936.

https://doi.org/10.1182/blood.V110.11.1936.1936

Published: 2007

Journal Articles

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nick Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1938.

https://doi.org/10.1182/blood.V110.11.1938.1938

Published: 2007

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3543.

https://doi.org/10.1182/blood.V110.11.3543.3543

Published: 2007

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Michael Rytting, MD, Deborah Thomas, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Gautam Borthakur, M.D., William Wierda, M.D., Cesar Nunez, M.D., Steven Kornblau, M.D., Farhad Ravandi, M.D., Robert Wells, M.D., Muriera Brenda, R.N., Franklin Anna, M.D., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4342.

https://doi.org/10.1182/blood.V110.11.4342.4342

Published: 2007

Journal Articles

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Jan Burger, M.D., Gautam Borthakur, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2958.

https://doi.org/10.1182/blood.V110.11.2958.2958

Published: 2007

Journal Articles

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Tai-Sung Lee, Steven Potts, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2917.

https://doi.org/10.1182/blood.V110.11.2917.2917

Published: 2007

Journal Articles

Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Dan Jones, Ph.D., Susan O’Brien, M.D., Mary Beth Rios, Jorge Cortes, M.D.

Blood (2007) 110 (11): 2961.

https://doi.org/10.1182/blood.V110.11.2961.2961

Published: 2007

Journal Articles

Dynamics of BCR-ABL1 Transcripts during Dasatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Dan Jones, Ph.D., Mary Beth Rios, Susan O’Brien, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2962.

https://doi.org/10.1182/blood.V110.11.2962.2962

Published: 2007

Journal Articles

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

Wanlong Ma, Iman Jilani, Ph.D., Benjamin Bekele, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Zhong Zhang, M.D., Susan O’Brien, M.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2837.

https://doi.org/10.1182/blood.V110.11.2837.2837

Published: 2007

Journal Articles

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Richard Tseng, PhD, Chen-Hsiung Yeh, Ph.D., Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Alison Hannah, Ph.D., Zeev Estrov, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2922.

https://doi.org/10.1182/blood.V110.11.2922.2922

Published: 2007

Journal Articles

Dasatinib-Induced Platelet Dysfunction.

Alfonso Quintas-Cardama, MD, Xin Han, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2941.

https://doi.org/10.1182/blood.V110.11.2941.2941

Published: 2007

Journal Articles

T Cell Blast Phase (T-BP) of Chronic Myelogenous Leuikemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4560.

https://doi.org/10.1182/blood.V110.11.4560.4560

Published: 2007

Journal Articles

Basophilic Blast Phase (B-BP) of Chronic Myelogenous Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4562.

https://doi.org/10.1182/blood.V110.11.4562.4562

Published: 2007

Journal Articles

Megakaryocytic Blast Phase (M-BP) of Chronic Myelogenous Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 4563.

https://doi.org/10.1182/blood.V110.11.4563.4563

Published: 2007

Journal Articles

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Wanlong Ma, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Susan O’Brien, M.D., Iman Jilani, Ph.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4546.

https://doi.org/10.1182/blood.V110.11.4546.4546

Published: 2007

NARROW

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Dynamics of BCR-ABL1 Transcripts during Dasatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Dasatinib-Induced Platelet Dysfunction.

T Cell Blast Phase (T-BP) of Chronic Myelogenous Leuikemia (CML).

Basophilic Blast Phase (B-BP) of Chronic Myelogenous Leukemia (CML).

Megakaryocytic Blast Phase (M-BP) of Chronic Myelogenous Leukemia (CML).

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only